SITC 2021 | Treating melanoma via fenofibrate and TIL transfer

Hildegund Ertl, MD, The Wistar Institute, Philadelphia, PA, describes the transfer of melanoma samples into mice to examine the treatment of melanoma with fenofibrate. In these pre-clinical models, the progression of melanoma has been shown to decelerate. Dr. Ertl explains the additional treatment of melanoma via tumor-infiltrating lymphocyte (TIL) transfer. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.